Olmesartan Medoxomil + Azelnidipine

Olmesartan/azelnidipine is a single-tablet, fixed-dose combination of two antihypertensive drugs that lower blood pressure through different mechanisms ^[1][3]. It brings together olmesartan medoxomil, an angiotensin II receptor blocker (ARB), and azelnidipine, a dihydropyridine calcium channel blocker (CCB). Combining a renin-angiotensin system blocker with a calcium channel blocker is a widely endorsed strategy in hypertension, because the two classes have additive effects and can partly offset each other's side effects ^[1].

Olmesartan medoxomil is a prodrug that the body converts to olmesartan, which selectively blocks the angiotensin II type 1 receptor. Azelnidipine is a long-acting dihydropyridine that, unlike some others in its class, produces a gradual blood-pressure reduction and tends not to raise heart rate, a property attributed to its action on calcium channels and its slow onset ^[1]. In Japan the pairing is sold as a single-pill product, while azelnidipine on its own is marketed there under the name CalBlock.

The combination is used to treat essential hypertension, generally in people whose blood pressure is not adequately controlled by one agent ^[2][3]. Clinical research in Japanese patients has compared it with other single-pill regimens. In one randomized trial, adding azelnidipine to olmesartan produced greater improvements in central blood pressure, arterial stiffness, and measures of left ventricular structure and function over two years than adding amlodipine to olmesartan, even though the two regimens lowered arm blood pressure to a similar degree ^[1]. Observational and database studies have reported that single-pill combinations of this kind are associated with better adherence and persistence than taking the same drugs as separate tablets ^[3], while comparisons of laboratory safety measures have found effects broadly similar to other ARB plus CCB single-pill products ^[2].

The fixed-dose olmesartan/azelnidipine tablet is a prescription medicine used mainly in Japan and some other Asian markets rather than in the United States or Europe, and it is available in more than one strength combination ^[2][3]. As a product containing a renin-angiotensin blocker, it shares the class precaution that such drugs should not be used during pregnancy.

This is a prescription combination that carries the effects of both drugs. It can cause dizziness, headache, flushing, and ankle swelling, though the swelling is usually less than with a calcium channel blocker alone because the ARB counteracts it. The olmesartan part can raise potassium, affect kidney function, and, rarely, cause a sprue-like enteropathy with severe diarrhea. Azelnidipine levels are raised by grapefruit juice, which should be avoided, and it can mildly slow the heart. The combination must not be used in pregnancy, and dual blockade of the renin system with ACE inhibitors should be avoided.

This single-pill product unites two agents developed by the Japanese company Sankyo, later Daiichi Sankyo. Olmesartan medoxomil, an angiotensin II receptor blocker, reached the market in 2002, while azelnidipine, a long-acting dihydropyridine calcium channel blocker, was approved in Japan in 2003 and sold there as Calblock. Recognizing that ARB plus calcium channel blocker is one of the most rational two-drug pairings for hypertension, Daiichi Sankyo combined them in a fixed-dose tablet marketed chiefly in Japan under the brand name Rezaltas, which was introduced in 2009.

The rationale was practical as well as pharmacological: a single tablet simplifies treatment for patients whose pressure is not controlled by one drug, while the two ingredients act on complementary control points. Azelnidipine itself is notable for a gradual onset that limits the reflex heart-rate rise seen with faster calcium channel blockers, a property that made it an attractive partner for olmesartan. The combination remains used primarily in Japan and a few other Asian markets rather than in Europe or North America.

The pairing is well regarded for delivering strong, complementary blood-pressure lowering from a single daily tablet, addressing two independent mechanisms at once and often achieving control where monotherapy falls short. Azelnidipine's characteristically slow, smooth action is a genuine highlight, since it tends not to provoke the reflex tachycardia and palpitations that patients sometimes dislike with quicker dihydropyridines, and blocking the renin-angiotensin system with olmesartan can blunt the ankle swelling that calcium channel blockers may cause.

Fixed-dose formats like this one are also valued for improving adherence, a decisive factor in a largely symptomless condition. Honesty requires noting that the combination is available mainly in Japan and some Asian markets, so its evidence base and familiarity are narrower than for the individual drugs, and a single pill offers less flexibility to fine-tune each dose. Within its market it is considered a convenient and effective option.